Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Aug;40(2):166–169. doi: 10.1111/j.1365-2125.1995.tb05772.x

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

S Wanwimolruk 1, M R Thou 1, D J Woods 1
PMCID: PMC1365178  PMID: 8562301

Abstract

The frequency distributions of the urinary metabolic ratios of debrisoquine and proguanil were measured in a population of unrelated Khmers. Out of 98 Khmer subjects studied, two were identified as poor metabolisers of debrisoquine when a metabolic ratio of 12.6 was used as the cut off point. This represents a prevalence of debrisoquine poor metabolisers of 2.1% (95% confidence interval 0.25-7.3%) which is similar to other Asian populations. Based on the distribution of the ratio of proguanil to cycloguanil excreted in urine, and using an antimode value of 10, the prevalence of poor metabolisers of proguanil in a Khmer population was estimated to be 18.4% (95% confidence interval 10.9-28.1%). The frequency of poor metabolisers of proguanil in Khmers was higher than that described for Caucasian populations, but similar to most reported results in Asian populations.

Full text

PDF
166

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Bechtel P., Iselius L., Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39(6):533–537. doi: 10.1007/BF00316090. [DOI] [PubMed] [Google Scholar]
  2. Benítez J., LLerena A., Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther. 1988 Jul;44(1):74–77. doi: 10.1038/clpt.1988.115. [DOI] [PubMed] [Google Scholar]
  3. Edstein M. D., Shanks G. D., Teja-Isavadharm P., Rieckmann K. H., Webster H. K. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol. 1994 Jan;37(1):67–70. doi: 10.1111/j.1365-2125.1994.tb04241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Helsby N. A., Ward S. A., Edwards G., Howells R. E., Breckenridge A. M. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol. 1990 Oct;30(4):593–598. doi: 10.1111/j.1365-2125.1990.tb03818.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Islam S. I., Idle J. R., Smith R. L. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica. 1980 Nov;10(11):819–825. doi: 10.3109/00498258009033812. [DOI] [PubMed] [Google Scholar]
  7. Jackson P. R., Tucker G. T., Woods H. F. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol. 1989 Dec;28(6):655–662. doi: 10.1111/j.1365-2125.1989.tb03558.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lee E. J., Nam Y. P., Hee G. N. Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol. 1988 Nov;15(11):889–891. doi: 10.1111/j.1440-1681.1988.tb01032.x. [DOI] [PubMed] [Google Scholar]
  9. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  10. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  11. Steiner E., Bertilsson L., Säwe J., Bertling I., Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 1988 Oct;44(4):431–435. doi: 10.1038/clpt.1988.176. [DOI] [PubMed] [Google Scholar]
  12. Taylor R. B., Moody R. R., Ochekpe N. A. Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography. J Chromatogr. 1987 May 15;416(2):394–399. doi: 10.1016/0378-4347(87)80526-1. [DOI] [PubMed] [Google Scholar]
  13. Wanwimolruk S., Denton J. R., Ferry D. G., Beasley M., Broughton J. R. Polymorphism of debrisoquine oxidation in New Zealand Caucasians. Eur J Clin Pharmacol. 1992;42(3):349–350. doi: 10.1007/BF00266364. [DOI] [PubMed] [Google Scholar]
  14. Wanwimolruk S., Patamasucon P., Lee E. J. Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol. 1990 Feb;29(2):244–247. doi: 10.1111/j.1365-2125.1990.tb03627.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ward S. A., Watkins W. M., Mberu E., Saunders J. E., Koech D. K., Gilles H. M., Howells R. E., Breckenridge A. M. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol. 1989 Jun;27(6):781–787. doi: 10.1111/j.1365-2125.1989.tb03440.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Watkins W. M., Mberu E. K., Nevill C. G., Ward S. A., Breckenridge A. M., Koech D. K. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):492–495. doi: 10.1016/0035-9203(90)90010-c. [DOI] [PubMed] [Google Scholar]
  17. Weerasuriya K., Jayakody R. L., Smith C. A., Wolf C. R., Tucker G. T., Lennard M. S. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol. 1994 Nov;38(5):466–470. doi: 10.1111/j.1365-2125.1994.tb04384.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES